Perrigo
PRGO · NYSE
$16.17+$0.08 (+0.50%)TodayMarket closed ·
Prev close $16.09
About PRGO
- Employees
- 8,100
- Headquarters
- DUBLIN, Dublin
- Listed
- Dec 17, 1991
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Website
- perrigo.com
Leadership
| Name | Title | Since |
|---|---|---|
| Orlando Ashford | — | — |
| Patrick Lockwood-Taylor | — | 2023 |
| Eduardo Bezerra | — | — |
| Robert Willis | — | — |
| Abigail Lennox | — | — |
| Charles Atkinson | — | — |
| David Ball | — | — |
| Roberto Khoury | — | — |
| Matt Winterman | — | — |
| Bradley Alford | — | — |
| Julia Brown | — | — |
| Kevin Egan | — | — |
| Adriana Karaboutis | — | — |
| Jeffrey Kindler | — | — |
| Albert Manzone | — | — |
| Donal O'Connor | — | — |
| Geoffrey Parker | — | — |
| Jonas Samuelson | — | — |
| Bradley Joseph | — | 2017 |
Revenue by product and region
Fiscal year ended Dec 31, 2025: $4.25B total revenue
By product
- Nutrition$408.50M9.6%
- Skin Care$407.70M9.6%
- Upper Respiratory$288.20M6.8%
- Pain and Sleep-Aids$235.40M5.5%
- Healthy Lifestyle$231.50M5.4%
- Other$509.70M12.0%
By region
- United States$2.54B59.7%
- Europe$1.62B38.0%
- All Other Countries$96.70M2.3%
- Ireland$42.10M1.0%
Suppliers and customers
Price correlation is over one year: 1 means the stocks move together, -1 opposite
| Company | Relationship | Correlation |
|---|---|---|
| BioLineRx BLRX | Supplier and customer | 0.86 |
| Sol-Gel Technologies SLGL | Supplier and customer | 0.84 |
| Acrux ACR.AX | Supplier and customer | 0.80 |
| Covetrus Inc CVET | Customer | 0.77 |
| Kaken Pharmaceutical | Supplier | 0.76 |
| Celltrion Healthcare | Supplier | 0.76 |
| Shield Therapeutics STX.L | Supplier and customer | 0.75 |
| Prothena PRTA | Supplier and customer | 0.71 |
| Ituran Location and Control ITRN | Supplier | 0.65 |
| Fine Foods & Pharms NTM FF.MI | Supplier | 0.62 |
Similar companies
Companies in the same industry as Perrigo
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.